Spain Patent System

Spain is the fourth-largest pharmaceutical market in Europe. Spain has a significant generic drug manufacturing industry, and Spanish courts and the OEPM have been active in pharmaceutical patent disputes. Key aspects: (1) Spanish pharmaceutical compulsory licensing history: Spain has invoked compulsory licensing provisions more actively than most EU countries. The most notable case involved Sofosbuvir (hepatitis C drug, brand name Sovaldi, Gilead Sciences) — Spain declared a public health emergency and was in discussions about compulsory licensing for Sovaldi given the drug's €45,000 per treatment course price vs. Spain's socialized healthcare system (Sistema Nacional de Salud) budget constraints. While full compulsory licenses were not issued, the pressure led to significant price negotiations. This reflects Spain's broader approach of using compulsory licensing as a negotiating lever; (2) SPCs in Spain: EU SPC Regulation 469/2009 applies directly. Spanish OEPM grants SPCs based on AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) marketing authorization date, which typically mirrors EMA authorization. Max SPC: 5 years + 6-month pediatric extension; (3) Pharmaceutical patent linkage: Spain implements EU pharmaceutical patent linkage — AEMPS requires generic drug marketing authorization applicants to certify that the reference product's relevant patents have expired, are not valid, or will not be infringed; (4) Biosimilars: Spain implements EU biosimilar guidelines; the Spanish NHS has an active biosimilar substitution policy — the Sistema Nacional de Salud has driven biosimilar adoption, making Spanish biosimilar cases important for EU market access strategy. Key Spanish pharma companies: Almirall (Barcelona — dermatology, respiratory), Grifols (Barcelona — plasma-derived therapies, a world leader), Faes Farma (Bilbao — antihistamines). Major global pharma companies have Spanish subsidiaries with significant R&D facilities (Janssen, Novartis, AstraZeneca, Roche).

Spain is the second-largest car manufacturer in Europe (after Germany by volume). The automotive industry generates significant patent activity. SEAT S.A. (now SEAT/Cupra, a Volkswagen Group company based in Martorell, Catalonia) is Spain's main car manufacturer and holds patents in EV powertrains, infotainment, connected vehicle technology, and design. Cupra (SEAT's performance/EV brand, launched 2018) has been particularly active in EV design patents. Stellantis operates major manufacturing plants in Spain (Zaragoza, Vigo) producing Opel/Vauxhall, Citroën, and Peugeot vehicles, with associated supplier patent ecosystems. Spain is also a world leader in renewable energy — second globally in installed wind capacity per capita. Key renewable energy patent activity: Gamesa (now Siemens Gamesa Renewable Energy, HQ Zamudio, Basque Country) is one of the world's largest wind turbine manufacturers and holds thousands of patents in blade technology, drivetrain, offshore foundations, and grid integration. Siemens Gamesa's patent portfolio is frequently cited in cleantech patent analyses. Iberdrola (Bilbao) is the world's largest renewable energy utility and holds patents in offshore wind, grid management, and energy storage. Acciona (Madrid) holds construction and renewable energy patents. Abengoa (Seville) — formerly active in concentrated solar power (CSP) patents, though corporate restructuring has affected its patent holdings.

Yes, Spain has joined the Unified Patent Court (UPC) system, though Spain was not among the founding states at the UPC's June 1, 2023 launch. Spain initially opposed the Unitary Patent and UPC structure — primarily over the language regime (the Unitary Patent is administered in English, German, and French, excluding Spanish, which Spain argued disadvantaged its language). After the UPC launched, Spain engaged in the ratification process and joined the UPC. Spain's UPC Local Division is in Madrid. The practical effects for patent holders: (1) New Unitary Patents (obtained after EP grant) now cover Spain along with other UPC participating states — one patent, one registration fee, EU-wide enforcement; (2) EP patents covering Spain that were not opted out of the UPC before the opt-out window closed can be litigated at the UPC Madrid Local Division. An injunction from the UPC is enforceable across all UPC participating states simultaneously; (3) For existing EP(ES) patents that were opted out: these continue as national Spanish patents, litigated in Spanish courts (primarily the Juzgados de lo Mercantil — Commercial Courts — and the Audiencia Provincial for appeals); (4) Pharmaceutical patent holders: Spain's large generic industry means pharmaceutical UPC cases in Madrid are expected to be significant, particularly for SPC validity challenges and Bolar exemption scope disputes. For most international applicants filing after Spain's UPC accession, the Unitary Patent is the most efficient route — one EPO application, one registration, coverage including Spain.

The Spanish Patent Act 2015 (Ley 24/2015 de Patentes, effective April 1, 2017) made several significant changes to Spanish patent law: (1) Most importantly: mandatory substantive examination. The 1986 Spanish Patent Act allowed applicants to obtain a patent WITHOUT substantive examination of novelty and inventive step (a 'registration' route). This produced many weak Spanish patents. Ley 24/2015 eliminated this — all Spanish national patent applications now require full examination by OEPM examiners. This aligned OEPM with EPO standards; (2) Post-grant opposition: the 2015 Act introduced a 9-month post-grant opposition procedure at OEPM (Art. 88), allowing third parties to challenge a patent's validity before OEPM shortly after grant. This is similar to the EPO post-grant opposition and reduces the burden on courts; (3) Updated biotechnology: full implementation of EU Biotechnology Directive 98/44/EC; (4) Clarified exhaustion: the community exhaustion doctrine was codified — parallel imports from other EU states are not patent infringement after the patent holder first put the product into the EU market; (5) Transitional provisions: patents granted under the 1986 Act (pre-April 2017) were not retroactively examined. This creates a two-tier landscape: pre-2017 OEPM patents (unexamined, potentially weak) and post-2017 OEPM patents (examined, more robust). This distinction matters for freedom-to-operate analyses and invalidity strategies involving Spanish national patents.

A Spanish utility model (Modelo de Utilidad) under Art. 137–150 of Ley 24/2015 provides 10 years of protection for novel and inventive objects, devices, or configurations of products. Key characteristics: (1) Registered without substantive examination: OEPM registers Spanish utility models after a formal examination and mandatory prior art search report — but OEPM does NOT examine for inventive step or novelty before registration. The utility model is registered quickly (typically 6–12 months) and can be asserted immediately, but validity is not confirmed by OEPM. In litigation, utility model validity is regularly challenged; (2) Lower inventive step: the inventive step standard for utility models is lower than for patents — the invention need only not be 'obviously derived' from prior art. Incremental improvements can qualify; (3) Objects/devices only: utility models cover configurations, structures, or combinations of objects that give them a particular utility or advantage. They do NOT cover processes, chemical compounds, or biotechnological material; (4) 10-year term, non-renewable: utility models cannot be renewed beyond 10 years. If protection beyond 10 years is needed, a patent application must be filed separately; (5) Cannot have both: you cannot hold a Spanish utility model and a Spanish patent on the same invention simultaneously; (6) When to use: Spanish utility models are useful for Spanish and EU SMEs, artisanal manufacturers, agricultural equipment makers, construction product manufacturers, and medical device companies with short product life cycles. The speed (6–12 months registration vs. 3–5 years for patent examination) is a significant advantage for market entry. The lower cost and lower inventive step bar make utility models a practical first line of protection. Note: SPC is NOT available for utility models — if pharmaceutical SPC is needed, a patent is required.

Spanish law (Article 15 of Ley 24/2015 de Patentes) addresses employee inventions in a framework similar to Germany and France, with three categories: (1) Employment-scope inventions (invencionas de servicio): inventions made in the execution of the employee's employment duties or based on significant employer-provided experience or resources. These belong to the employer. For this category: the employer must formally communicate the decision to claim ownership to the employee within 3 months of the employee's disclosure — failure to communicate within 3 months means the employer loses the right to claim the invention; (2) Occasional use of employer resources: inventions made outside the employee's employment duties but using significant employer resources, know-how, or experience. The employer has the right to assume ownership (or an exploitation license) within 3 months of employee disclosure, upon payment of fair compensation (compensación equitativa) to the employee. The compensación equitativa is determined considering the personal contribution of the employee, the importance of the invention, and the value of the employer's contribution; (3) Free inventions: inventions made entirely outside employment duties, without using employer resources, in unrelated fields. These belong entirely to the employee. For US companies with Spanish employees: like Germany and France, Spanish law requires employers to claim ownership within a 3-month window after employee disclosure — missing this window forfeits the employer's rights. Employment agreements should include explicit assignment provisions for employment-scope inventions, but the mandatory compensación equitativa for exceptional-value inventions cannot be contractually waived.

The European Union Intellectual Property Office (EUIPO) — which manages EU trademarks (EUTMs) and Registered Community Designs (RCDs) for the entire EU — has its headquarters in Alicante, Spain. The location was agreed politically in 1994 during the establishment of the original OHIM (which became EUIPO in 2016), with Spain receiving the office in exchange for EU institutional positioning. Effect on Spanish IP practice: (1) The EUIPO location creates a concentration of EU trademark and design legal expertise in Spain, particularly in the Valencia region. Spanish IP law firms have significant specialization in EU trademark and design practice; (2) For EU trademark (EUTM) and design (RCD) work, Spanish practitioners are well-positioned to handle EUIPO proceedings — oppositions, cancellations, and appeals to the EUIPO Boards of Appeal (also in Alicante). Appeals from EUIPO Boards of Appeal go to the General Court of the EU (Luxembourg) and ultimately the CJEU; (3) For patent strategy specifically, EUIPO does NOT handle patents (patents are handled by EPO, national patent offices, or the UPC for Unitary Patents). However, many IP matters involve both patents AND trademarks/designs — particularly in Spain's luxury goods, fashion, food and beverages (wine/olive oil Geographical Indications also handled at EU level), and automotive sectors. Spanish IP attorneys and firms typically handle the full IP spectrum; (4) EUIPO's location in Spain makes Spain a practical hub for EU IP dispute work, with Spanish courts having experience in EU trademark and design litigation that cross-influences their IP judicial culture generally.